IN8bio’s Promising Clinical Trial Results and Strategic Developments Justify Buy Rating

IN8bio (INAB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from JonesTrading maintained a Buy rating on the stock and has a $1.20 price target.

Soumit Roy has given his Buy rating due to a combination of factors related to IN8bio’s recent clinical trial results and strategic developments. The company presented promising data from their Phase 1 trial of INB-200 in glioblastoma patients, showing a median progression-free survival (mPFS) of 16.1 months, which significantly surpasses historical benchmarks. This performance is notable compared to the standard of care and previous trials, indicating a potential breakthrough in treatment efficacy.
Additionally, the ongoing stability in some patients and the absence of new safety concerns further bolster the therapeutic’s profile. IN8bio’s strategic focus on their leukemia program and potential partnerships for further development also contribute to a positive outlook. These factors collectively suggest a strong potential for growth and success, justifying the Buy rating.

Roy covers the Healthcare sector, focusing on stocks such as Precision BioSciences, IN8bio, and Elicio Therapeutics. According to TipRanks, Roy has an average return of -25.7% and a 18.07% success rate on recommended stocks.